Clinical Trial Update: INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

View source ↗

Summary

A real-world, completed evaluation of nintedanib for changes in cough and dyspnea in patients with chronic fibrosing interstitial lung disease with a progressiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Status: COMPLETED